A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)

Inclusion Criteria: * Adult participants with low or intermediate-1 risk MDS * No previous treatment with hematopoietic growth factors within 3 months prior to screening * Symptomatic anemia (hemoglobin \<10 g/dL) as determined by investigator * Serum erythropoietin \<500 milliunits/milliliter (mU/mL) within 14 days prior to the first dose of study treatment * Require no red blood cell transfusion or dependent on \<4 units within 8 weeks prior to screening * Clinically stable for at least 1 month prior to entry into the study * For female participants of childbearing potential and male participants with partners of childbearing potential, agreement (by participants and/or partner) to use highly effective form(s) of contraception Exclusion Criteria: * Contraindications and/or known hypersensitivity to the active substance and/or any of the excipients of epoetin beta treatment * Poorly controlled hypertension as assessed by the investigator * History of Acute Myeloid Leukemia (AML) or high risk for AML * Administration of another investigational drug within 1 month before screening or planned during the study period * Previously documented evidence of Pure Red Cell Aplasia (PRCA)